Dulaglutide, liraglutide and subcutaneous semaglutide have been approved for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus with established cardiovascular disease, dulaglutide is approved for use in type 2 diabetes mellitus with multiple risk factors, and both liraglutide and semaglutide have been approved for chronic weight management
Patients also report acid reflux, stomach pain, vomiting, and diarrhea
received honoraria for speaking at meetings from Novartis, Sanofi-Aventis, Lilly, AstraZeneca, Boehringer Ingelheim, and NovoNordisk
But Dushay points out that although GLP-1s have been prescribed for 20 years, there has been little precedent for a medication to be used as quickly, as widely, or as long term for so many different ailments
(2016) 4:e00239